Inozyme Pharma Acquisition Finalized by BioMarin

The acquisition of Inozyme Pharma Inc. by BioMarin Pharmaceutical Inc. has been completed, marking the end of the company's tenure as a publicly traded entity. The all-cash transaction, valued at approximately $270 million, was finalized on July 1, 2025. Shareholders of Inozyme received a cash payment of $4.00 per share, concluding the investment timeline for former stockholders.

BioMarin first publicized the acquisition agreement on May 16, 2025. The purchase was executed through BioMarin's subsidiary, Incline Merger Sub, Inc., as a straightforward cash deal. A subsequent tender offer concluded on June 30, 2025, with about 70% of Inozyme's outstanding shares being tendered. Prior to market open on July 1, the merger was officially completed. All remaining shares not tendered were automatically converted into the right to receive the same $4.00 per share in cash. Consequently, Inozyme's stock has been delisted from the Nasdaq Global Select Market and is no longer available for public trading.

Strategic Asset: The INZ-701 Therapy

Central to this corporate move is the drug candidate INZ-701, an enzyme replacement therapy in late-stage development. It targets two rare genetic disorders: ENPP1 Deficiency and ABCC6 Deficiency. Previous Phase 1/2 clinical trial data indicated a favorable safety profile for the treatment, alongside observed improvements in pyrophosphate levels and biomarkers for bone mineralization. In January 2025, Inozyme reported positive interim results from its ENERGY-1 study and an expanded access program. The U.S. Food and Drug Administration (FDA) had previously granted INZ-701 Fast Track designation for ABCC6 Deficiency in July 2024. This acquisition allows BioMarin to strategically broaden its portfolio in the enzyme replacement therapy sector.

Should investors sell immediately? Or is it worth buying Inozyme Pharma Inc?

Path Forward and Implications

All future development and potential commercialization efforts for INZ-701 now fall under BioMarin's purview. Key clinical milestones are on the horizon, with topline results from the first Phase 3 registrational study in children anticipated in early 2026. A potential regulatory approval for the therapy could follow in 2027. For former Inozyme investors, the process is complete following the $4.00 per share cash payout. No further independent market updates or analyst coverage for Inozyme (formerly ticker: INZY) will be issued, as the company is now privately held within the larger BioMarin organization.

Key Deal Facts:
* Cash Consideration: $4.00 per share
* Finalization Date: July 1, 2025
* Tender Result: Approximately 70% of shares tendered
* Listing Status: Delisted from Nasdaq
* Next Major Catalyst: Phase 3 clinical data expected early 2026